AR086287A1 - Composicion inmunoestimulante, metodo - Google Patents
Composicion inmunoestimulante, metodoInfo
- Publication number
- AR086287A1 AR086287A1 ARP120101591A ARP120101591A AR086287A1 AR 086287 A1 AR086287 A1 AR 086287A1 AR P120101591 A ARP120101591 A AR P120101591A AR P120101591 A ARP120101591 A AR P120101591A AR 086287 A1 AR086287 A1 AR 086287A1
- Authority
- AR
- Argentina
- Prior art keywords
- antagonist
- ilt
- antigenic peptides
- receptors
- disease
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 239000005557 antagonist Substances 0.000 abstract 6
- 230000000890 antigenic effect Effects 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 210000004443 dendritic cell Anatomy 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 5
- 108020003175 receptors Proteins 0.000 abstract 5
- 102000005962 receptors Human genes 0.000 abstract 5
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 abstract 3
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 abstract 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 abstract 3
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 abstract 3
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 abstract 3
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 abstract 3
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 abstract 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000002500 effect on skin Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- -1 antibodies Proteins 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una composición inmunoestimulante que comprende uno o más péptidos antigénicos, donde los péptidos antigénicos son representativos de uno o más epitopes de uno o más antígenos que participan en una enfermedad o una afección contra la cual pudiera resultar deseable estimular la respuesta inmune y/o en una enfermedad o una afección que se deseara prevenir y/o tratar; y al menos un antagonista de los receptores de los transcriptos tipo inmunoglobulina (ILT), donde los receptores de los ILT se seleccionan del grupo que consiste en el ILT2, el ILT4, el ILT5 y las combinaciones de éstos y pueden expresarse en una o más células dendríticas (DC) dérmicas CD14+.Reivindicación 13: La composición de la reivindicación 1, donde los antagonistas de los receptores de los ILT son moléculas pequeñas, proteínas solubles, proteínas de fusión, anticuerpos, fragmentos de anticuerpos, polipéptidos o cualquier combinación de éstos. Reivindicación 14: Una vacuna que comprende uno o más péptidos antigénicos y al menos un antagonista que inhibe la unión de los receptores de los transcriptos tipo inmunoglobulina (ILT) a CD8, que es apropiada para administrarla en las células dendríticas (DC) dérmicas CD14+, donde los péptidos antigénicos y el antagonista se proveen en una cantidad eficaz para provocar una respuesta inmune y/o para poner en práctica un tratamiento terapéutico y/o profiláctico en un sujeto humano o en un animal. Reivindicación 17: La vacuna de la reivindicación 14, donde el antagonista es un antagonista del ILT2, del ILT4 o del ILT5. Reivindicación 31: Una composición inmunoestimulante o una vacuna con la que puede prevenirse y/o tratarse una enfermedad provocada por un virus, por una bacteria, por un hongo, por un parásito o por un protozoo o un trastorno alérgico a través de la activación de una o más células dendríticas (DC), donde la composición inmunoestimulante puede producirse aislando una o más DC de un sujeto humano, exponiendo las una o más DC aisladas a uno o más péptidos antigénicos y combinándolas con al menos un antagonista de los receptores de los transcriptos tipo inmunoglobulina (ILT), donde los péptidos antigénicos son representativos de uno o más epitopes de uno o más antígenos que participan en una enfermedad o una afección contra la cual pudiera resultar deseable estimular la respuesta inmune y/o en una enfermedad o una afección que se deseara prevenir y/o tratar, y donde los receptores de los ILT se seleccionan del grupo que consiste en el ILT2, el ILT4, el ILT5 y las combinaciones de éstos y pueden expresarse en una o más células dendríticas (DC) dérmicas CD14+.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482859P | 2011-05-05 | 2011-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086287A1 true AR086287A1 (es) | 2013-12-04 |
Family
ID=47108079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101591A AR086287A1 (es) | 2011-05-05 | 2012-05-04 | Composicion inmunoestimulante, metodo |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120315269A1 (es) |
| AR (1) | AR086287A1 (es) |
| TW (1) | TW201247700A (es) |
| WO (1) | WO2012151578A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| WO2011091181A1 (en) * | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
| CA2949081C (en) | 2014-05-16 | 2023-03-07 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
| JP6533912B2 (ja) * | 2014-05-22 | 2019-06-26 | フレッド ハッチンソン キャンサー リサーチ センター | Ｌｉｌｒｂ２およびｎｏｔｃｈを介した造血前駆細胞の拡大培養 |
| EP3209769B1 (en) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| WO2016065245A1 (en) | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| CN107456578A (zh) * | 2016-06-03 | 2017-12-12 | 硕英生医股份有限公司 | 一种关闭病原体的免疫抑制功能的方法及其用途 |
| CN107236025B (zh) * | 2017-03-30 | 2019-10-18 | 中山大学 | 与cd56分子特异性结合的多肽及其应用 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| EP3728318A2 (en) | 2017-12-22 | 2020-10-28 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| CN108226016A (zh) * | 2018-01-12 | 2018-06-29 | 浙江普罗亭健康科技有限公司 | 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒 |
| PE20211604A1 (es) | 2018-07-09 | 2021-08-23 | Five Prime Therapeutics Inc | Anticuerpos de union a ilt4 |
| TWI866327B (zh) | 2019-12-23 | 2024-12-11 | 南韓商Ｌｇ化學股份有限公司 | 抗ｌｉｌｒｂ１抗體和彼之用途 |
| CN112147326B (zh) * | 2020-09-04 | 2022-04-08 | 北京大学 | 一种肿瘤免疫细胞亚群分型精准检测试剂盒 |
| CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
| CN114736308B (zh) * | 2022-03-15 | 2022-12-27 | 四川宜美康科技有限公司 | 球虫抗原肽/il5的融合蛋白基因工程菌的制备及用途 |
| CN118010601B (zh) * | 2024-04-07 | 2024-06-18 | 中国医学科学院北京协和医院 | 一种用于诊断原发性胆汁性胆管炎的系统 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090114430A (ko) * | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신 |
-
2012
- 2012-05-04 AR ARP120101591A patent/AR086287A1/es unknown
- 2012-05-04 TW TW101116115A patent/TW201247700A/zh unknown
- 2012-05-07 US US13/465,371 patent/US20120315269A1/en not_active Abandoned
- 2012-05-07 WO PCT/US2012/036797 patent/WO2012151578A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW201247700A (en) | 2012-12-01 |
| US20120315269A1 (en) | 2012-12-13 |
| WO2012151578A1 (en) | 2012-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086287A1 (es) | Composicion inmunoestimulante, metodo | |
| Maue et al. | An ESAT-6: CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis | |
| CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
| Smyth et al. | Continuous acquisition of MHC: peptide complexes by recipient cells contributes to the generation of anti-graft CD8+ T cell immunity | |
| Hessenberger et al. | Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores | |
| JP2013517331A5 (es) | ||
| FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
| JP2014509841A5 (es) | ||
| NZ590991A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| Vordermeier et al. | Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting | |
| CN109310746A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| Antonio-Herrera et al. | The nontoxic cholera B subunit is a potent adjuvant for intradermal DC-targeted vaccination | |
| Picchio et al. | Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice | |
| Kochetkova et al. | Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27 | |
| Saenz et al. | HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen | |
| WO2007130555A3 (en) | Augmentation of immune response to cancer vaccine | |
| Wagner et al. | Prime-boost vaccination with Toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice | |
| van’t Land et al. | Regulatory T-cells have a prominent role in the immune modulated vaccine response by specific oligosaccharides | |
| Nouri et al. | Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants | |
| Krashias et al. | Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer | |
| MX369925B (es) | Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria. | |
| Liu et al. | The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18 | |
| Azizi et al. | Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection | |
| Joseph et al. | Single multivalent vaccination boosted by trickle larval infection confers protection against experimental lymphatic filariasis | |
| HRP20200160T1 (hr) | Peptidi desmogleina 3 za pemphigus vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |